Curis(CRIS)2025-05-06 12:03Financial Performance - Curis reported a net loss of $10.6 million or $1.25 per share for Q1 2025, compared to a net loss of $11.9 million or $2.05 per share in Q1 2024[8]. - Revenues for Q1 2025 were $2.4 million, an increase from $2.1 million in Q1 2024, primarily from royalty revenues from Genentech/Roche's sales of Erivedge®[8]. - Research and development expenses decreased to $8.5 million in Q1 2025 from $9.6 million in Q1 2024, mainly due to lower employee-related costs[9]. - General and administrative expenses also decreased to $4.0 million in Q1 2025 from $4.9 million in Q1 2024, attributed to lower employee-related and consulting costs[9]. - Curis has approximately $20.3 million in cash and cash equivalents as of March 31, 2025, which is expected to support operations into Q4 2025[11]. - Curis completed a registered direct offering and private placement with net proceeds of approximately $8.8 million[7]. Clinical Development - The company is currently enrolling patients in the TakeAim Lymphoma study to enable accelerated approval filings for emavusertib in both the EU and US[3]. - Emavusertib has received Orphan Drug Designation for PCNSL in both the U.S. and Europe[5]. - The TakeAim Lymphoma study has provided data updates for 27 patients, including 20 BTK-experienced and 7 BTK-naïve patients[5]. - Curis aims to expand emavusertib's application beyond PCNSL into additional indications in NHL, AML, and solid tumors[4].